吸入・点鼻スプレーのジェネリック医薬品市場：適応症別、年齢層別、薬剤クラス別、ルート別、流通チャネル別-2025-2030年の世界予測

吸入・点鼻スプレーのジェネリック医薬品市場は、2023年に80億9,000万米ドルと評価され、2024年には87億8,000万米ドルに達すると予測され、CAGR 8.61％で成長し、2030年には144億3,000万米ドルに達すると予測されています。

吸入・点鼻スプレーのジェネリック医薬品市場の範囲は、主に喘息、COPD、アレルギー性鼻炎などの呼吸器疾患に使用される薬剤の広いスペクトルを包含します。これらのジェネリック医薬品は、ブランド薬に代わる費用対効果の高い代替品を提供し、必要不可欠な治療法へのアクセスを拡大します。ジェネリック医薬品の必要性は、世界中で呼吸器疾患やアレルギーの有病率が増加していることから生じており、主に病院、診療所、在宅医療の現場で使用されています。最終用途の範囲は年齢層を超えており、小児と成人の両方に対応しています。成長に影響を与える要因としては、慢性呼吸器疾患の罹患率の上昇、ジェネリック医薬品の使用を促進する政府の取り組み、医療費抑制策などが挙げられます。さらに、いくつかの大ヒット吸入薬の特許が切れたことで、ジェネリック医薬品メーカーに有利なビジネスチャンスが広がっています。特に、費用対効果の高いヘルスケアソリューションに対する需要が高まっている新興市場において、地理的な範囲を拡大することに潜在的なビジネスチャンスがあります。規制当局の承認プロセスを合理化し、流通網を強化することで、市場でのプレゼンスをさらに強固なものにすることができます。しかし、市場の成長は、厳しい規制のハードル、大手企業間の高い競合、先発医薬品と比較したジェネリック医薬品の生物学的同等性に関する潜在的な問題などの課題に直面しています。製造能力の限界や、治療上の同等性やデバイスの革新を達成するための研究開発への高額投資の必要性も大きな障壁となっています。技術革新の面では、アドヒアランスを向上させ、リアルタイムで使用データを提供するデジタル吸入器など、高度なドラッグデリバリー・システムの開発に成長の機会があります。個別化医療の調査、特定の患者層をターゲットにした製剤の最適化、吸入器の環境に優しい推進剤への注力なども潜在的な研究分野です。市場はダイナミックで競争が激しく、継続的な進歩により、市場シェアを効果的に獲得するための戦略的イノベーションと適応の必要性が高まっています。

市場力学：急速に進化する吸入・点鼻スプレーのジェネリック医薬品市場の主要市場インサイトを公開

吸入・点鼻スプレーのジェネリック医薬品市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ジェネリック処方薬の低コスト化
  • 呼吸器疾患の有病率の増加
  • 小児用ネブライザーの大幅な普及
• 市場抑制要因
  • ジェネリック医薬品に対する厳しい規制
• 市場機会
  • ブロックバスター医薬品の特許切れとFDA承認の増加
  • 製薬会社による研究開発投資の増加
• 市場の課題
  • このセグメントにおける複数のプレーヤーの存在による価格圧力

ポーターの5つの力：吸入・点鼻スプレーのジェネリック医薬品市場をナビゲートする戦略ツール

ポーターの5つの力」フレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：吸入・点鼻スプレーのジェネリック医薬品市場における外部からの影響の把握

外部マクロ環境要因は、吸入・点鼻スプレーのジェネリック医薬品市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析吸入・点鼻スプレーのジェネリック医薬品市場における競合情勢の把握

吸入・点鼻スプレーのジェネリック医薬品市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス吸入・点鼻スプレーのジェネリック医薬品市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、吸入・点鼻スプレーのジェネリック医薬品市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ジェネリック医薬品の低コスト
    • 呼吸器疾患の罹患率の増加
    • 小児用ネブライザーの大幅な導入
  • 抑制要因
    • ジェネリック医薬品に対する厳しい規制
  • 機会
    • ブロックバスター医薬品の特許切れとFDA承認の増加
    • 製薬会社の研究開発投資の増加
  • 課題
    • 複数のプレーヤーが存在するため価格圧力が高まっている
• 市場セグメンテーション分析
  • 適応症：アレルギー性鼻炎のジェネリック医薬品による迅速かつ即時の症状緩和の必要性
  • 年齢層：2～5歳の子供向けの製品開発を強化
  • 流通チャネル：競争力のある価格と利便性を提供するオンライン薬局の人気が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ
  • 処方と投与装置の変更

第6章 吸入・点鼻スプレーのジェネリック医薬品市場適応症別

• アレルギー性鼻炎
• 喘息
• 慢性閉塞性肺疾患

第7章 吸入・点鼻スプレーのジェネリック医薬品市場：年齢層別

• 大人
• 2歳から5歳までの子供
• 6歳から12歳までの子供

第8章 吸入・点鼻スプレーのジェネリック医薬品市場：クラス別

• アレルギーブロッカー
• 抗コリン剤
• 抗ヒスタミン薬
• 充血除去薬
• 肥満細胞抑制剤
• 鼻用ステロイド

第9章 吸入・点鼻スプレーのジェネリック医薬品市場：ルート別

• 吸入
• 鼻スプレー
• トロピカルローション

第10章 吸入・点鼻スプレーのジェネリック医薬品市場：流通チャネル別

• 病院医療用品店
• オンライン薬局
• 薬局小売業

第11章 南北アメリカの吸入・点鼻スプレーのジェネリック医薬品市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の吸入・点鼻スプレーのジェネリック医薬品市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの吸入・点鼻スプレーのジェネリック医薬品市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ユージアファーマ、ブデソニドジェネリックの米国FDA承認を取得
  • アンファスター・ファーマシューティカルズ、ナロキソン塩酸塩点鼻薬4mgのFDA承認を取得
  • アムニール、ナロキソン塩酸塩点鼻薬（USP、4mg）の簡略新薬申請が米国FDAに受理されたと発表

企業一覧

• Chiesi Farmaceutici S.p.A.
• Altaire Pharmaceuticals Inc.
• Apotex Inc.
• Amphastar Pharmaceuticals, Inc.
• Hikma Pharmaceuticals PLC
• Sun Pharmaceutical Industries Ltd.
• Cipla Limited
• AstraZeneca PLC
• Sandoz International GmbH
• Viatris Inc.
• AbbVie Inc.
• Nephron Pharmaceuticals Corporation
• Zhejiang Xianju Pharmaceutical Co., Ltd.
• Preferred Pharmaceuticals, Inc.
• Acerus Pharmaceuticals Corporation
• Mylan N.V.
• Beximco Pharmaceuticals Ltd.
• Akorn, Inc.
• Perrigo Company PLC
• GlaxoSmithKline PLC
• Nippon Shinyaku Co., Ltd.
• Sanofi S.A.
• Padagis US LLC
• AptarGroup, Inc.
• Recipharm AB
• Teva Pharmaceutical Industries Ltd.
• Catalent, Inc.

LIST OF FIGURES

• FIGURE 1. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COPD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 2 TO 5, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CHILDREN 6 TO 12, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ALLERGY BLOCKER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ANTIHISTAMINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DECONGESTANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY MAST CELL INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL STEROID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY TROPICAL LOTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY HOSPITAL MEDICAL STORE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY PHARMACY RETAIL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 48. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 49. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 50. CANADA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 75. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 76. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 77. CHINA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 80. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 81. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 82. INDIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 165. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 166. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 167. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 168. ITALY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 184. POLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 185. POLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 186. POLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 187. POLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 188. POLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. QATAR INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 190. QATAR INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 191. QATAR INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 192. QATAR INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 193. QATAR INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 239. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 240. INHALATION & NASAL SPRAYS GENERIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Inhalation & Nasal Sprays Generic Drugs Market was valued at USD 8.09 billion in 2023, expected to reach USD 8.78 billion in 2024, and is projected to grow at a CAGR of 8.61%, to USD 14.43 billion by 2030.

The scope of the inhalation and nasal sprays generic drugs market encompasses a wide spectrum of medications used primarily for respiratory conditions such as asthma, COPD, and allergic rhinitis. These generic drugs offer cost-effective alternatives to branded medications, expanding access to essential therapies. Necessity for these drugs arises from the increasing prevalence of respiratory diseases and allergies worldwide, fueling their application primarily in hospitals, clinics, and homecare settings. End-use scope spans across age groups, catering to both pediatric and adult populations. Influencing growth factors include the rising incidence of chronic respiratory ailments, government initiatives to promote generic drug usage, and healthcare cost containment measures. Additionally, the expiration of patents for several blockbuster inhalation drugs opens lucrative opportunities for generics manufacturers. Potential opportunities lie in expanding geographical reach, particularly in emerging markets where demand for cost-effective healthcare solutions is mounting. Streamlining the regulatory approval process and enhancing distribution networks can further solidify market presence. Yet, market growth faces challenges such as stringent regulatory hurdles, high competition among leading players, and potential issues related to the bioequivalence of generics compared to brand-name counterparts. Limitations in manufacturing capabilities and the necessity for high investment in R&D to achieve therapeutic equivalence and device innovation are also significant barriers. On the innovation front, opportunities for growth lie in the development of advanced drug-delivery systems, such as digital inhalers that improve adherence and provide real-time usage data. Research into personalized medicine, optimizing formulations to target specific patient demographics, and focusing on eco-friendly propellants in inhalers are other potential areas of exploration. The market is dynamic and competitive, with continuous advancements fostering a need for strategic innovation and adaptation to capture market share effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Inhalation & Nasal Sprays Generic Drugs Market

The Inhalation & Nasal Sprays Generic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Low Cost Involved with Generic Prescription Drugs
  • Increasing Prevalence of Respiratory Diseases
  • Significant Adoption of Nebulizers for Children
• Market Restraints
  • Stringent Regulations For Generic Drugs
• Market Opportunities
  • Patent Expiry of Blockbuster Drugs and Increasing FDA Approvals
  • Growing Investments from Pharmaceutical Companies for R&D
• Market Challenges
  • Pricing Pressure due to Presence of Multiple Players in the Segment

Porter's Five Forces: A Strategic Tool for Navigating the Inhalation & Nasal Sprays Generic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Inhalation & Nasal Sprays Generic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Inhalation & Nasal Sprays Generic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Inhalation & Nasal Sprays Generic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Inhalation & Nasal Sprays Generic Drugs Market

A detailed market share analysis in the Inhalation & Nasal Sprays Generic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Inhalation & Nasal Sprays Generic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Inhalation & Nasal Sprays Generic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Inhalation & Nasal Sprays Generic Drugs Market, highlighting leading vendors and their innovative profiles. These include Chiesi Farmaceutici S.p.A., Altaire Pharmaceuticals Inc., Apotex Inc., Amphastar Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Cipla Limited, AstraZeneca PLC, Sandoz International GmbH, Viatris Inc., AbbVie Inc., Nephron Pharmaceuticals Corporation, Zhejiang Xianju Pharmaceutical Co., Ltd., Preferred Pharmaceuticals, Inc., Acerus Pharmaceuticals Corporation, Mylan N.V., Beximco Pharmaceuticals Ltd., Akorn, Inc., Perrigo Company PLC, GlaxoSmithKline PLC, Nippon Shinyaku Co., Ltd., Sanofi S.A., Padagis US LLC, AptarGroup, Inc., Recipharm AB, Teva Pharmaceutical Industries Ltd., and Catalent, Inc..

Market Segmentation & Coverage

This research report categorizes the Inhalation & Nasal Sprays Generic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Indication, market is studied across Allergic Rhinitis, Asthma, and COPD.
• Based on Age Group, market is studied across Adults, Children 2 to 5, and Children 6 to 12.
• Based on Class, market is studied across Allergy Blocker, Anticholinergic, Antihistamine, Decongestant, Mast Cell Inhibitor, and Nasal Steroid.
• Based on Route, market is studied across Inhalation, Nasal Spray, and Tropical Lotion.
• Based on Distribution Channel, market is studied across Hospital Medical Store, Online Pharmacy, and Pharmacy Retail.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Low Cost Involved with Generic Prescription Drugs
    • 5.1.1.2. Increasing Prevalence of Respiratory Diseases
    • 5.1.1.3. Significant Adoption of Nebulizers for Children
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent Regulations For Generic Drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Patent Expiry of Blockbuster Drugs and Increasing FDA Approvals
    • 5.1.3.2. Growing Investments from Pharmaceutical Companies for R&D
  • 5.1.4. Challenges
    • 5.1.4.1. Pricing Pressure due to Presence of Multiple Players in the Segment
• 5.2. Market Segmentation Analysis
  • 5.2.1. Indication: Need for quick and immediate symptom relief generic medications for allergic rhinitis
  • 5.2.2. Age Group: Increasing product development for children aged 2 to 5
  • 5.2.3. Distribution Channel: Growing popularity of online pharmacies offering competitive pricing and convenience
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization
  • 5.5.1. Changing Formulation & Delivery Device

6. Inhalation & Nasal Sprays Generic Drugs Market, by Indication

• 6.1. Introduction
• 6.2. Allergic Rhinitis
• 6.3. Asthma
• 6.4. COPD

7. Inhalation & Nasal Sprays Generic Drugs Market, by Age Group

• 7.1. Introduction
• 7.2. Adults
• 7.3. Children 2 to 5
• 7.4. Children 6 to 12

8. Inhalation & Nasal Sprays Generic Drugs Market, by Class

• 8.1. Introduction
• 8.2. Allergy Blocker
• 8.3. Anticholinergic
• 8.4. Antihistamine
• 8.5. Decongestant
• 8.6. Mast Cell Inhibitor
• 8.7. Nasal Steroid

9. Inhalation & Nasal Sprays Generic Drugs Market, by Route

• 9.1. Introduction
• 9.2. Inhalation
• 9.3. Nasal Spray
• 9.4. Tropical Lotion

10. Inhalation & Nasal Sprays Generic Drugs Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Medical Store
• 10.3. Online Pharmacy
• 10.4. Pharmacy Retail

11. Americas Inhalation & Nasal Sprays Generic Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Inhalation & Nasal Sprays Generic Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Inhalation & Nasal Sprays Generic Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Eugia Pharma Gets USFDA Nod for Budesonide Generic
  • 14.3.2. Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
  • 14.3.3. Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

Companies Mentioned

• 1. Chiesi Farmaceutici S.p.A.
• 2. Altaire Pharmaceuticals Inc.
• 3. Apotex Inc.
• 4. Amphastar Pharmaceuticals, Inc.
• 5. Hikma Pharmaceuticals PLC
• 6. Sun Pharmaceutical Industries Ltd.
• 7. Cipla Limited
• 8. AstraZeneca PLC
• 9. Sandoz International GmbH
• 10. Viatris Inc.
• 11. AbbVie Inc.
• 12. Nephron Pharmaceuticals Corporation
• 13. Zhejiang Xianju Pharmaceutical Co., Ltd.
• 14. Preferred Pharmaceuticals, Inc.
• 15. Acerus Pharmaceuticals Corporation
• 16. Mylan N.V.
• 17. Beximco Pharmaceuticals Ltd.
• 18. Akorn, Inc.
• 19. Perrigo Company PLC
• 20. GlaxoSmithKline PLC
• 21. Nippon Shinyaku Co., Ltd.
• 22. Sanofi S.A.
• 23. Padagis US LLC
• 24. AptarGroup, Inc.
• 25. Recipharm AB
• 26. Teva Pharmaceutical Industries Ltd.
• 27. Catalent, Inc.